Ther Clin Risk Manag. 2007 Oct;3(5):725-32.
To evaluate progression rates with dorzolamide compared with other hypotensive agents in primary open-angle glaucoma.
Patients who were treated over 5 years with dorzolamide versus other hypotensive agents were reviewed. The groups were matched by intraocular pressure, cardiovascular history, and age.
In 50 matched pairs, 2 (4%) of dorzolamide and 7 (14%) of control patients suffered glaucomatous progression (p = 0.09). Progressed dorzolamide patients had pressures of 13 versus 15-20 mmHg in the control group. Control patients progressed after 26.4 months and dorzolamide patients after 38.9 months.
Although the results were not statistically significant, this pilot trial demonstrated a trend towards less glaucomatous progression in patients treated with an assumed active blood flow product. In addition, progression was delayed and occurred at lower pressures in the active blood flow group. This pilot trial suggests that future prospective, long-term, clinical outcomes studies in patients treated with a medicine with a positive ocular blood flow effect may be warranted.
评估与其他降血压药物相比，多佐胺在原发性开角型青光眼患者中的进展率。
回顾了使用多佐胺治疗超过 5 年的患者与使用其他降血压药物治疗的患者。通过眼压、心血管病史和年龄对两组进行匹配。
在 50 对匹配的患者中，多佐胺组有 2 例（4%）患者和对照组有 7 例（14%）患者发生青光眼进展（p = 0.09）。进展的多佐胺组患者的眼压为 13mmHg，而对照组为 15-20mmHg。对照组患者在 26.4 个月后进展，多佐胺组患者在 38.9 个月后进展。
尽管结果没有统计学意义，但这项初步试验表明，在使用假定具有积极血流产物的药物治疗的患者中，青光眼进展的趋势较少。此外，在积极血流组中，进展被延迟且发生在较低的压力下。这项初步试验表明，未来可能需要对接受具有积极眼血流效应的药物治疗的患者进行前瞻性、长期临床结局研究。
